Chlamydia pneumoniae has been associated with cardiovascular diseases, and C. pneumoniae infection is treatable with macrolides. In this comparative cohort study, 634 users of macrolides and 3827 users of penicillins were identified from the Danish Health Service Registry of Prescriptions and followed up for an average of 6 months. The patients were then linked to the Regional Hospital Discharge Registry to assess the outcome of hospitalization for cardiovascular disease. In the first 3 months, the relative risk ( 
effect seems to be reduced after a follow-up of 180 days [13] . Other studies have not been able to show an effect of macrolide treatment on acute coronary syndromes after 6 months of follow-up [14] . Two case-control studies of the effect of macrolides on risk of first-time myocardial infarction have been published. Meier et al. [15] found no association when macrolides were prescribed in the previous 3 years, nor did Jackson et al. [16] , who assessed macrolide treatment in the year preceding myocardial infarction.
Macrolides, in contrast to penicillins, have an antimicrobial effect on C. pneumoniae. The optimal treatment regimen is, however, not known, and it could be hypothesized that the current recommended courses of macrolide therapy may have an effect of only short duration on cardiovascular diseases. In this prospective comparative cohort study, we therefore assessed the time-dependent effect of macrolide therapy compared with penicillin therapy on the risk of hospitalization due to cardiovascular disease in subjects aged 50-69 years.
Population and Methods
Study population. Aarhus County, Denmark, has ∼600,000 inhabitants. Those 50-69 years old ( ) were chosen as the n p 151,000 study population.
Exposure data. The Danish National Health Service provides tax-supported health care to all inhabitants, ensuring free access to general practitioners and hospitals and refunding a variable portion of the costs of drugs prescribed by physicians. The National Health Service, Aarhus County, retains key information about prescriptions for refundable drugs dispensed from all of the pharmacies in the county. This information includes the personal identification number of the customer, type of drug prescribed according to the anatomic therapeutic chemical classification system, and the date of prescription. The personal identification number comprises 10 digits that encode sex and date of birth.
In the present study, information on prescriptions of macrolides and penicillins was collected from 1 March to 1 November 1998. During these 8 months, we identified 634 users of macrolides and 3827 users of penicillins. These were the 2 cohorts of the study. Antibiotics are prescribed only by doctors in Denmark. Cephalosporins, tetracyclines, or quinolones are not subsidized by the Danish government, and the effect of these antibiotics could therefore not be assessed.
Outcome data. The 2 cohorts were linked to the regional Hospital Discharge Registry (HDR) in Aarhus County, which retains on a permanent basis key information on all patients discharged from all hospitals in the county since 1994. The files of the HDR include the identification number of the patient, date of discharge, and up to 20 discharge diagnoses, coded according to the Danish version of the International Classification of Diseases, 10th revision (ICD-10). By use of the HDR, we collected information about any discharge diagnosis of cardiovascular disease before and after the prescription of antibiotics. The codes for discharge diagnoses of cardiovascular diseases were the following: ICD-10 I20-I20.9, angina pectoris; ICD-10 I21-I22.9, acute myocardial infarction; ICD-10 I23-I23.8, complications of acute myocardial infarction; ICD-10 I46-I46.9, cardiac arrest; ICD-10 I50-I50.9, heart failure; ICD-10 I63-I63.9, cerebral infarction; ICD-10 I64-I64.9, stroke; ICD-10 I65-I66.9, occlusion and stenosis of precerebral arteries; ICD-10 I70-I70.9, atherosclerosis of arteries of extremities; ICD-10 I71-I71.9, aortic aneurysms; ICD-10 I74-I74.9, arterial thrombosis; and ICD-10 I80-I80.9, thrombophlebitis.
The diagnoses of interest with regard to confounders and independent risk factors included hypertension, diabetes mellitus types 1 and 2, hypercholesterolemia, and chronic obstructive pulmonary disease (COPD). The latter was used as a proxy measure for smoking. Information on these risk factors was obtained from 2 sources. One was by "looking back" in the HDR for a period of 4 years before the prescription of macrolides or penicillins to see if the patient had a discharge diagnosis for any of the risk factors. The other source was the registry of prescriptions, which was searched for prescriptions for any drugs being used to treat any of the risk factors. Thus, information on the risk factors was also sought among patients being treated for their risk factor in an outpatient setting.
Statistical analyses. The follow-up period regarding hospitalization began on the date of the prescription and ended at the day of admission to hospital, the date of death, or the end of the study (19 January 1999) . Patients treated with both macrolides and penicillins during the study period were excluded from analyses. Patients were included only once in the study, and only the cardiovascular diagnosis that first was obtained was used as the outcome.
A Cox proportional hazard model was used to estimate the relative risk of hospitalization due to cardiovascular disease, adjusted for confounders (sex, previous cardiovascular disease, hyperten- sion, hypercholesterolemia, type 1 diabetes, type 2 diabetes, and COPD). In all models, the age was the basic time scale; that is, persons in the study cohort were first at risk from their age at inclusion into the study and until a cardiovascular event or censoring due to death or study end.
By use of the PROC PHREG procedure in SAS 6.12 (SAS Institute), the proportional hazards assumption was evaluated by assessing the parallelism of the log integrated hazard function for each of the study covariates. Models were stratified by variables that did not satisfy this assumption.
We examined interaction by use of product terms in the Cox models and by stratified analyses. To examine trends in the relative risks more closely, time-dependent covariates were incorporated into the models, reflecting the relative risk in disjoint time intervals: 0-3 months after treatment with macrolide (exposure), 3-6 months after treatment, and 16 months after treatment.
Results
During the study period, the 4461 users of the 2 antibiotics contributed a total of 2385 person-years of observation. A total of 335 patients had an admission with a discharge diagnosis of cardiovascular disease during the study period, corresponding to an overall cumulative incidence of 14.0%. The baseline characteristics of the study population are shown in x p 5.5 P ! .02 The distribution of discharge diagnoses that previously has been associated with C. pneumoniae is shown in table 2. Statistical significance could not be reached for any particular cardiovascular disease, presumably in part because of the low number of events for each cardiovascular disease. However, the reduced risk of admission in users of macrolides compared with penicillins seems not to be associated with any particular cardiovascular disease.
The relative risk (RR) of hospitalization for cardiovascular disease was dependent on the time interval after prescription of the macrolides. Thus, during the first 3 months, there was benefit from macrolide therapy compared with penicillin therapy (RR, 0.48; 95% confidence interval [CI], 0.27-0.88; P p ), but this effect was not statistically significant after the first .02 3 months of follow-up (figure 1).
We found interaction between the effect of macrolides and the following variables, which were therefore stratified: no previous hospitalization due to cardiovascular disease, age, and sex. The RRs during the first 3 months of follow-up for each of these strata are shown in table 3, and, as shown in figure 2 , the same time-dependent pattern for the RR seen for the total group was found for each of the 3 strata. Thus, during the first 3 months of follow-up, the effect of macrolide treatment was more pronounced for patients with no previous history of cardiovascular disease (figure 2A), patients у60 years old (figure 2B), and men (figure 2C).
Discussion
Use of macrolides was associated with a subsequent reduced risk for hospitalization for a cardiovascular disease, compared with use of penicillins. The effect lasted for 3 months only and was associated with being male, being у60 years old, and not having had a previous cardiovascular disease.
The main strengths of our study are the uniformly organized Danish health care system, which allows a population-based design that avoids selection bias introduced by differential patient recruitment, as in studies from referral centers; the ability to adjust for the hospital discharge history of cardiovascular disease; and the completeness of follow-up. Selection bias is unlikely in a design that relies on computerized linkage of registries with almost complete coverage for the study area. Patients treated with penicillins were chosen as the comparator because this group is a more appropriate reference group than, for example, the background population. This is so because a group treated with penicillins is more similar with regard to comorbidity (e.g., lung disease) and underlying risk of cardiovascular disease than are groups not being treated with antibiotics. For instance, there is an increased risk of having a cardiovascular event after having respiratory tract symptoms [17] , and although we do not know the indications for prescribing the antibiotics, we know from previous studies that respiratory tract infection is the major indication for prescribing macrolides and penicillins in Denmark. Thus, if a healthy control group had been chosen instead of a group of penicillin users, the effect of macrolides would have been overestimated.
It is well known that hospital discharge diagnoses vary in quality, and we relied on the coding of the hospital discharge diagnoses by hospital doctors at the time of discharge [18] . The validity of a diagnosis of acute myocardial infarction has previously been found to be high [19] , whereas it was lower for a diagnosis of hypertension [18] . This potential nondifferential classification tends to give conservative estimates of the risk. A strategy of analyses considering all cardiovascular diagnoses as outcomes was chosen because there is some misclassification of the discharge diagnosis. Any bias of this strategy is toward the null hypothesis, and our estimates are therefore conservative. In other words, the evidence for any association would be stronger if a difference can be shown for the whole group of cardiovascular diagnoses instead of just specific diagnoses. Although there was a trend of the effect of macrolides being found for all disease categories, we were not able to show a statistically significant difference in risk of hospitalization for any particular category of diagnosis. This may, however, be explained by the low number of events in each of the groups.
It is well known that compliance is not complete for antibiotics, and we did not have information on dose or duration of the antibiotics. This may introduce bias. However, any noncompliance, low compliance, and misclassification of the exposure will bias the study toward the null hypothesis and thus underestimate the real effect. As seen from our data, macrolide prescription was associated with COPD, which, in turn, is related to smoking, which is a risk factor for cardiovascular disease. That more patients with COPD were treated with macrolides than with penicillins also tends to underestimate the observed effect of macrolides in comparison with penicillins.
The lower risk of hospitalization for cardiovascular disease in macrolide users was transient, and we were not able to show a beneficial effect of macrolides 3 months after the prescription. The finding of a dependency between the time of macrolide use and the admission for a cardiovascular disease strengthens the evidence for an association between macrolides and reduced risk of cardiovascular disease. In addition, the finding of a short-term effect is in accordance with the findings of Gurfinkel et al. [12] , who found an effect of roxithromycin therapy after 30 days, but not after 180 days, when given to patients with an acute cardiovascular disease (secondary prophylaxis) [13] .
Meier et al. [15] showed that patients developing a myocardial infarction were less likely than patients not developing myocardial infarction to have been treated with quinolones and tetracyclines, but they did not find any association between acute myocardial infarction and macrolide therapy. However, Meier et al. [15] assessed the risk over a period of 3 years, and an effect of short duration might therefore have been overlooked. In addition, they controlled only for age, sex, general practice attended, and calendar time, although the regression analysis was adjusted for smoking status and body mass index. Both may explain the difference from the results of our study. In another meticulous case-control study by Jackson et al. [16] , no relationship was found between first-time myocardial infarction and use of erythromycin, tetracycline, or doxycycline, even when assessment was restricted to use of the antibiotics 1 year before the myocardial infarction. These findings again support our findings of only a short-term effect of macrolides.
We did not investigate the effect of quinolones, tetracyclines, or cephalosporins, because these drugs are not subsidized by the Danish government, and thus data regarding these drugs are not reported to the register. The use of these drugs in Denmark is, however, negligible, and it is not likely that data on the use of these drugs would have changed the results.
The mechanisms behind the beneficial effect of macrolides on cardiovascular diseases are not known. Some mechanisms that have been postulated include a stabilizing effect on asymptomatic atherosclerotic plaques that otherwise might have ruptured and led to subsequent thrombosis. Such stabilization may be due to an antichlamydial effect, whereby the growth of this organism is inhibited. This is supported by the fact that the antichlamydial drugs tetracycline and quinolones may also have a beneficial effect [15] . However, a direct anti-inflammatory effect on diseased vessels is also a possibility, because some macrolides have an anti-inflammatory effect [20] , which is in part due to a direct inhibitory action on neutrophils and several cytokines [21] .
Because of limitations of comparative population-based cohort studies, the data obtained in this study do not justify a change in current prescription guidelines. However, the data provide a unique background for designing blinded, randomized, and controlled clinical trials assessing the effect of macrolides on cardiovascular events in men у60 years old with no previous cardiovascular disease. Such studies should also include a careful evaluation of adverse events as well as an evaluation of the potential environmental impact that the prophylactic use of macrolides may have on the development of antimicrobial resistance.
